The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Calcium Resonium 99.934 % Powder for oral or rectal suspension

99.934 percent weight/weight Powder for oral suspension

Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/141/001

Main Information

Trade NameCalcium Resonium 99.934 % Powder for oral or rectal suspension
Active SubstancesCalcium polystyrene sulphonate
Strength99.934 percent weight/weight
Dosage FormPowder for oral suspension
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/141/001

Group Information

ATC CodeV03AE Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE01 polystyrene sulfonate

Status

Authorised/WithdrawnAuthorised
Licence Issued01/04/1983
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back